Grindeks provides a wide range of development, analytical, and manufacturing services to support all stages of API and Final dosage form development – from early stages to GMP production.
Grindeks and its subsidiaries hold MIA and GMP certificates, as well as authorizations for IMPs and controlled substances.

Company (Headquarters):

Latvia

Types of Drugs Manufactured:

Small Molecule

CDMO Services:

Drug Substance Manufacturing (API);Drug Product/FDF;Research & Development;Packaging(Commercial);Analytical Development;Process & Forumulation Development

Therapeutic Area:

Cardiovascular;Central Nervous System;Dermatology;Gastrointestinal and Metabolism;Oncology;Pain Symptoms

CDMO Number of Facilities:

3

High Potent Products capabilities:

OEB 3 Medium Potency;OEB 4-5 Highly Potent APIs (HPAPIs)

Facilities Location:

Europe

Regulatory Approvals for facilities:

USA - FDA;Europe - EMA or constituent countries;GMP;ISO 9001;ISO 14001;WHO

Manufacturing Technologies:

Creams/Gels/Ointments;Oral Liquids;Sterile Ampoules;Tablets/Capsules